aminomebendazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 40320 |
| CHEMBL ID | 2030560 |
| CHEBI ID | 172478 |
| SCHEMBL ID | 416899 |
| MeSH ID | M0520350 |
| Synonym |
|---|
| AKOS005442025 |
| CHEBI:172478 |
| (2-amino-3h-benzimidazol-5-yl)-phenylmethanone |
| 52329-60-9 |
| g-1029 , |
| r 18986 |
| 2-amino-5-benzoylbenzimidazole |
| methanone, (2-amino-1h-benzimidazol-5-yl)phenyl- |
| ketone, 2-amino-6-benzimidazolyl phenyl |
| ketone, 2-amino-5-benzimidazolyl phenyl |
| benzimidazole, 2-amino-5-benzoyl- |
| OPREA1_430354 |
| OPREA1_702808 |
| EU-0000069 |
| (2-amino-1h-benzimidazol-6-yl)(phenyl)methanone |
| STK395314 |
| FT-0661589 |
| AKOS005228561 |
| bdbm50383377 |
| chembl2030560 , |
| (2-amino-3h-benzimidazol-5-yl)-phenyl-methanone |
| unii-x6y3ded23d |
| aminomebendazole |
| r-18986 |
| x6y3ded23d , |
| (2-amino-1h-benzimidazol-5-yl)phenylmethanone |
| mebendazole-amine |
| g 1029 |
| (2-amino-1h-benzimidazol-6-yl)phenylmethanone |
| 2-amino-5-benzoyl-1h-benzimidazole |
| 2-amino-5(6)-benzoylbenzimidazole |
| methanone, (2-amino-1h-benzimidazol-6-yl)phenyl- |
| mebendazole impurity a [ep impurity] |
| 2-amino-5-benzoylimidazole |
| SCHEMBL416899 |
| GPMHHSJZGVOEFS-UHFFFAOYSA-N |
| 2-amino-5-benzoyl-benzimidazole |
| DTXSID70200353 |
| mebendazole-amine, vetranal(tm), analytical standard |
| SR-01000087529-1 |
| sr-01000087529 |
| 2-amino-5 benzoylbenzimidazole |
| (2-amino-1h-benzimidazol-5-yl)(phenyl)methanone |
| 2-amino-5-benzoylbenzo[d]imidazole |
| (2-amino-1h-benzo[d]imidazol-5-yl)(phenyl)methanone |
| HY-114750 |
| mebendazole-amine 100 microg/ml in acetonitrile |
| CS-0064241 |
| r18986 |
| Q27293617 |
| G1029 , |
| SY291828 |
| mfcd01529678 |
| (2-amino-3h-benzoimidazol-5-yl)-phenyl-methanone |
| 6-benzoyl-1h-1,3-benzodiazol-2-amine |
| Class | Description |
|---|---|
| benzophenones | Any aromatic ketone in which the carbonyl group is bonded to 2 phenyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0001 | 0.7128 | 10.0000 | AID672953 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | Ki | 10.0000 | 0.0002 | 1.3996 | 10.0000 | AID660980 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0002 | 0.5335 | 10.0000 | AID672954 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.1897 | 0.8200 | AID660979 |
| Calmodulin-domain protein kinase 1 | Toxoplasma gondii | IC50 (µMol) | 0.2300 | 0.2300 | 0.4500 | 0.6700 | AID672956 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID660979 | Inhibition of human SRC by radiometric assay | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. |
| AID1215964 | Drug level in human liver microsomes treated with 10 uM mebendazole after 19.83 mins by HPLC-MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes. |
| AID1632104 | Binding affinity to recombinant human N-terminal His6 and Avi-tagged FABP6 expressed in Escherichia coli NEB cells by surface plasmon resonance method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6). |
| AID672954 | Inhibition of human SRC | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. |
| AID660978 | Inhibition of Cryptosporidium parvum CDPK1 by nonradioactive Kinaseglo luciferase assay | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. |
| AID672955 | Inhibition of Cryptosporidium parvum CDPK1 | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. |
| AID1632105 | Binding affinity to recombinant human N-terminal His6 and Avi-tagged FABP6 expressed in Escherichia coli NEB cells at 250 uM by surface plasmon resonance method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6). |
| AID672953 | Inhibition of human ABL | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. |
| AID672945 | Cytotoxicity against human CRL8155 cells after 48 to 72 hrs by Alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. |
| AID1215966 | Drug level in human liver S9 fraction treated with 10 uM mebendazole after 19.80 to 20.76 mins by HPLC-MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes. |
| AID672949 | Antiparasitic activity against Cryptosporidium parvum up to 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. |
| AID672950 | Antiparasitic activity against Toxoplasma gondii up to 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. |
| AID660980 | Inhibition of human ABL by radiometric assay | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. |
| AID660977 | Inhibition of N-terminal hexaHis-tagged Toxoplasma gondii CDPK1 expressed in Escherichia coli BL21* by nonradioactive Kinaseglo luciferase assay | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. |
| AID672946 | Cytotoxicity against human HL60 cells after 48 to 72 hrs by Alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. |
| AID672956 | Inhibition of Toxoplasma gondii CDPK1 | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16 | Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||